Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Tax Provisions (2017 - 2025)

Autolus Therapeutics' Tax Provisions history spans 6 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 180.92% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached $2.0 million, up 29.08%, while the annual FY2025 figure was $2.0 million, 29.06% up from the prior year.
  • Tax Provisions reached -$1.2 million in Q4 2025 per AUTL's latest filing, down from $532000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $19.6 million in Q4 2022 to a low of -$1.2 million in Q4 2025.
  • Average Tax Provisions over 4 years is $1.4 million, with a median of $8500.0 recorded in 2022.
  • Peak YoY movement for Tax Provisions: tumbled 320.0% in 2023, then soared 27912.5% in 2025.
  • A 4-year view of Tax Provisions shows it stood at $19.6 million in 2022, then crashed by 100.12% to -$24000.0 in 2023, then skyrocketed by 6191.67% to $1.5 million in 2024, then crashed by 180.92% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Tax Provisions are -$1.2 million (Q4 2025), $532000.0 (Q3 2025), and $397000.0 (Q2 2025).